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Poor medication adherence is problematic among HIV positive, low-income African-American 
substance users. Substance use has been shown to be associated with poor medication adherence, 
though we do not know the mechanism that underlies this relationship. Lack of positive 
environmental rewards and the propensity to discount delayed rewards may be possible 
mechanisms to explain this relationship. Using baseline data from a randomized controlled trial, 
we examined the relationships between substance use and medication adherence, testing both 
environmental rewards and delay discounting as independent mediators. There was a main effect 
of substance use on adherence, such that high frequency of substance use predicted poor 
adherence. There was also a main effect of environmental rewards on adherence, such that a lack 
of environmental reinforcement predicted poor adherence. This study shed light on the processes 
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1 .251* -.357** .033 -.102 -.030 -.072 .127 
Past Year 
Substance Use 
 1 .129 -.004 .063 -.057 -.162 -.004 
RPI total   1 .125 .153 .037 -.077 .091 
Large K 
values 
   1 .809** .695** .064 -.157 
Medium K 
values 
    1 .817** -.010 -.156 
Small K 
values 
     1 .004 -.104 
CD4 Count        1 -.129 
Viral Load         1 
HAART         
Mean  11.76 7 55.10 .0499 .0583 .0786 455.34 4462.02 
SD 8.65 4.6 8.01 .0729 .0806 .0798 248.84 21495.86 
Minimum  0 0 40 .000251 .000632 .000160 17 20 
Maximum  31 20 74 .248848 .250000 .250000 1033 128000 
Not on 
HAART 
        
Mean  11.34 9.2 56.06 .0286 .0377 .0472 413.63 38667 
SD 9.2 3.79 9.02 .0498 .0549 .0536 29.46 69592.76 
Minimum  0 0 33 .000158 .000160 .000160 8 300 
Maximum  36 17 77 .248848 .250000 .159085 810 242320 
 
 
Table 1.  
Means, Standard deviations, and bi-variate correlations of key study variables 
*Correlation is significant at p < 0.05 








Substance Use Frequencies (entire sample) 
 Alcohol   Cocaine  Marijuana  Opioid  
Never 20% 25.3% 54.9% 72.6% 
One time 1.3% 6.7% 7.0% 4.1% 
Monthly or 
less 
12% 5.3% 15.5% 2.7% 
2-4 
times/month 
13.3% 5.3% 7.0% 0% 
2-3 times/week 13.3% 20% 1.4% 4.1% 
4 or more 
times/week 
40% 37.3% 14.1% 16.4% 
 
Table 2.  































Substance Use Correlations  
 
 Alcohol   Cocaine  Marijuana  Opioid  
Alcohol  1 .393** .162 -.042 
Cocaine   1 -.042 .062 
Marijuana    1 -.101 
Opioid     1 
 
Table 3.  
Bi-variate correlations between past year Alcohol, Marijuana, Cocaine, and Opioid Use  
*Correlation is significant at p < 0.05 
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   -.002        6.993 
 
Figure 1. 
Unstandardized estimates for the relation between substance use, environmental rewards, delay discounting, and 















Substance Use Medication Adherence  





Adherence to Highly Active Antiretroviral Therapy (HAART) 
 An estimated 1.1 million people in the United States are living with HIV (CDC, 2012).  
In the era of highly active antiretroviral therapy (HAART), morbidity and mortality as a result of 
HIV/AIDS has been declining (Crum et al., 2006). However, for HAART to be effective in 
controlling the progression of HIV/AIDS, adherence to a strict medication regimen must be near 
perfect (Shuter, Sarlo, Kanmaz, Rode, & Zingman, 2007).  Despite the importance of near 
perfect adherence for disease management, actual rates of HAART adherence are low, ranging 
from 4-30% (Paterson, Swindells, Mohr, Brester, Vergis, Squier, C., et al., 2000; Golin, Liu, 
Hays, Miller, Beck, Ickovics, Kaplan, & Wenger, 2002).  There are significant public health 
implications for low adherence in general, but the negative consequences of low adherence are 
especially prominent among groups that show disparities in terms of higher incidence of 
HIV/AIDS, such as low-income African-Americans (CDC, 2011; Kuo, Greenberg, Magnus, 
Phillips, Rawls, Peterson, et al., 2011; DC Department of Health, 2010, Golin, et al., 2002).   
 Across chronic health conditions, medication adherence is imperative for improving 
health outcomes, which is particularly relevant for individuals living with HIV, as there are often 
medical comborbidities in this population that require strict adherence to medication (Altice, 
Kamarulzaman, Soriano, Schechter, & Friedland, 2010). Near perfect adherence to HAART is 
necessary for viral suppression (Bangsberg et al., 2001; Bangsberg et al., 2006), and 
nonadherence and inconsistent adherence is related  to a greater likelihood of producing strands 
of HIV that are of medication-resistant, additional health complications, and increased morbidity 
and mortality (Garcia de Olalla, Knobel, Carmona, Guelar, Lopez-Colomes, & Cayla, 2002). 
Due to the important individual health consequences and larger public health implications of 
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non-adherence or low adherence to various medications in this population, it is imperative to 
study the factors that contribute to these low rates of adherence for substance users.  
Substance use and medication adherence 
 One well-researched factor that contributes to low medication adherence in general 
among HIV positive individuals is substance use.  This relationship is particularly important 
because the incidence of substance use among HIV infected individuals in the U.S. is high, with 
estimates of HIV and co-occurring substance use ranging from 40-74% (Bing et al, 2001; 
McGowan, Weinstein, Samenow, Stinnette, Barkanic, Rebeiro, & Hulgan, 2011; Skeer, 
Mimiaga, Mayer, O’Cleirigh, Covahey, & Safren, 2012). Regarding HIV medication 
specifically, numerous studies have found support for the relation between substance use and 
poor HAART adherence across different drug classes.  For example, Arnsten and colleagues 
(2002) examined drug use as a predictor of HAART adherence among past or current opioid 
users who have HIV, and found cocaine use to be among the strongest predictors of low HAART 
adherence as measured by an electronic cap (MEMS cap; Arnsten, Demas, Grant, Gourevitch, 
Farzadegan….& Schoenbaum (2002).  Additionally, Stein and colleagues (2000) found ongoing 
drug use to be significantly associated with decreased HAART adherence in a sample of 
outpatient methadone users.  Hinkin and colleagues found that substance abuse was associated 
with sub-optimal adherence in a sample of outpatients seeking HIV care (Hinkin, Hardy, Mason, 
Castellon, Durvasula, Lam, & Stefaniak, M., 2004).  Moreover, in a review of 41 studies of 
adherence to HAART among substance users, Malta and colleagues (2008) found that active 
substance use was associated with poorer adherence overall.  Additionally, a review by Gonzalez 
and colleagues (2011) summarized the extant literature regarding the impact of substance use on 
HIV medical treatment, and concluded that substance use significantly impacts effective disease 
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management for people living with HIV/AIDS (PLWHA) due to low rates of medication 
adherence.   
 In addition to the correlation between substance use and low adherence, HIV positive 
substance users experience unique barriers to medication adherence.  For example, a study of 
injection drug users living with HIV/AIDS found individual barriers to adherence (i.e. low 
positive attitude about HAART benefits, limited medical coverage, current drug use), suggesting 
that there are factors within the context of HIV positive substance users that warrant examination 
(Knowlton, A. R., Arnsten, J. H., Eldred, L. J., Wilkinson, J. D., Shade, S. B., Bohnert, A. S., ... 
& Purcell, D. W. (2010).  The literature suggests a strong relation between substance use and 
medication adherence among PLWHA.  Despite the relation between these constructs, we have a 
limited understanding of the mechanisms that underlie this relationship, and the extant literature 
has yet to elucidate why substance use is related to poor adherence among HIV positive 
substance users. 
Research on mechanisms 
 Improving our understanding of the relation between substance use and low adherence 
may serve to inform targeted interventions. Although there is evidence to support the relation 
between substance use and adherence, little is known about potential mechanisms that underlie 
this relationship (Arnsten et al, 2002; Peretti-Watel et al, 2006; Golin et al, 2002; Hinkin et al., 
2007). Behavioral reasons (e.g. avoiding medication due to unpleasant side effects and 
complexity of medication regimen) are the most common factor underlying missed medication 
doses, highlighting the importance of studying behavioral mediators (Chesney, 2003). It has been 
shown that engaging in substance use treatment (especially substitution therapy) is a protective 
factor against low adherence among HIV positive substance users, perhaps due to engagement in 
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structured daily routines (Malta et al., 2008). Thus, this suggests that behavioral treatment for 
substance use might have a positive impact on adherence.  Many investigators call for integration 
of substance use treatment and treatments for adherence (Safren et al., 2009; Tucker et al., 2004; 
Hinkin et al., 2007), and there are behavioral treatments developed based on behavioral theories 
that aim to decrease substance use and increase adherence (Daughters et al., 2010). Though there 
is evidence to support the efficaciousness of these behavioral treatments, the mechanisms that 
underlie their success is unknown. This focus on behavioral treatments boosts the argument to 
investigate behavioral mechanisms in order to develop targeted treatments.   
Theoretical framework for the relationship between substance use and low adherence 
 In an effort to understand mechanisms underlying the relationship between substance 
users and poor adherence, it is useful to begin with a clear theoretical framework.  A behavioral 
perspective (Skinner, 1953: Bandura and Walters, 1963; Bandura, 1969) might be particularly 
useful when conceptualizing this relationship.  It is well documented that substance use is 
developed and maintained as a result of a lack of alternative, substance-free reinforcement in the 
environment (Carroll, 1996; Higgins, Heil, & Lussier, 2004; Daughters et al., 2008). If substance 
users experience a lack of positive reinforcement from the environment, they may place less 
value on a healthy lifestyle, which includes adhering to a complex medication regimen.  
Furthermore, the principles that underlie substance use maintenance are indeed similar to those 
that underlie medication nonadherence; specifically the reinforcers for substance use behaviors 
or nonadherence behaviors are immediate, and the reinforcers for the opposite behaviors 
(abstinence from drug use; adherence to a medication) regimen are delayed.  Using this as a 
framework for conceptualizing the relationship between substance use and low adherence among 
PLWHA, potential mechanisms can be identified to explain this relationship.    
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Lack of positive reinforcement in the environment 
 One potential mechanism in the relationship between substance use and poor adherence 
based in basic behavioral theory is a lack of access to rewards from non-substance related 
activities that occur in the environment.  If substance users are experiencing a lack of positive 
reinforcement from the environment for non-substance using activities because they are not 
accessing rewards from living a healthy and active life, with substance use being the primary 
source of reward, they may be less inclined to take their medication as prescribed given its role 
in achieving a healthy life. The association between substance use and lack of access to 
environmental contingencies is well documented (Correia et al., 2005; Van Etten et al., 1998; 
Murphy et al., 2005), though questions remain regarding directionality.  
There is some evidence that substance use directly impacts an individuals’ lack of access 
to non-substance based environmental contingencies. Substance users reliably rate reinforcement 
from non-substance using activities as less reinforcing than controls (Correia et al., 2005; Van 
Etten et al. 1998). In a study examining environment based contingencies among cocaine-
dependent individuals, individuals who were abstinent from cocaine for 24 hours increased the 
frequency of engagement in non-substance using activities (Van Etten et al. 1998). In a 
longitudinal study of 18-22 year olds, lack of alternative reinforces in the environment predicted 
cigarette smoking over a four-year period (Audrain-McGovern et al. 2011). Additionally, a 
prospective study investigating adults with heroin dependence found that ratings of non-
substance stimuli negatively predicted future heroin use (Lubman et al. 2009). The link between 
these processes is likely bidirectional in that lack of access to environmental contingencies is a 
risk factor for the development of substance use, and once an individual is addicted, they do not 
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access (and subsequently do not receive positive reinforcement from) non-drug related activities 
in the environment.     
 Although the relationship between lack of positive reinforcement from the environment 
and adherence among HIV+ substance users has not been examined, there is evidence that 
positive reinforcement may be important in these self-care behaviors because the direct effects of 
medication alone is not sufficient to promote continued and accurate adherence.  Thus, 
individuals who exhibit low adherence or non-adherence may require additional reinforcement 
from the environment in order to engage in self-care behaviors (Chesney, 2003; Chesney et al., 
2000).   
Propensity to discount delayed rewards 
 In addition to lack of positive reinforcement from the environment, there are other 
characteristics of a reinforcer that may be important for understanding why substance users have 
poor adherence.  For example, one characteristic is the timing of the reinforcer.  Thus, another 
mechanism in the relationship between substance use and poor adherence based in reinforcement 
theory is the propensity to discount a reward based on its delay.  Delay discounting involves 
discounting the value of delayed rewards in favor of more immediate rewards (Bickel & Marsch, 
2001).  From the perspective of delayed reward discounting, because some of the unpleasant 
consequences of taking daily medication are often immediate (i.e. side effects, reminder of HIV 
status, medication regimen complications), it may be easy to choose the immediate reward of 
avoidance, so as not to experience such unpleasantness.  This value of immediate rewards results 
in a discounting of delayed rewards, mainly improved health outcomes such as lower viral load 
and increased longevity.  Indeed, one of the most established reasons why people do not take 
their medication is due to immediate unpleasant side effects (Ammassari et al, 2002; Chesney, 
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2000; Fogarty et al, 2002).  The side effects may operate as a negative stimulus and thus may 
result in choosing the immediate reward of avoidance behavior (i.e., not taking the medication as 
prescribed) in order to avoid the potentially punishing aspects of these side effect profiles.  This 
results in non-adherence to medication, despite the large but delayed potential positive outcomes 
of adherence (decreased viral load and lower risk of mortality).  Substance use might be related 
to poor adherence because substance users discount the value of delayed rewards in favor of 
immediate rewards, and this propensity contributes to low adherence based on the timing of the 
reward (discounting delayed reward of healthy medication adherence in favor of immediate 
rewards of avoidance).    
 The link between substance use and the propensity to value immediate rewards over 
delayed, uncertain ones is well-established (Madden et al., 1997; Mitchell, 1999; Vuchinich & 
Simpson, 1998; Kirby & Petry, 2004; Yi et al., 2008).  There is a wealth of literature to suggest 
substance users discount delayed rewards at higher rates than their non-drug using counterparts 
(Bickel et al., 1998; Bickel and Marsh, 2001; Kirby, Petry, & Bickel, 1999; Petry 2001; 
MacKillop, Amlung, Few, Ray, Sweet, & Munafò, 2011). Though there is evidence that 
substance use impacts the propensity to discount delayed rewards (Mendez, Simon, Hart, 
Mitchell, Nation, Wellman, & Setlow, 2010), the preponderance of evidence suggests that the 
propensity to discount delayed rewards precedes the development of substance use (Perry, 
Larson, German, Madden, & Carroll, 2005; Marusich & Bardo, 2009). Despite the lack of clarity 
regarding directionality (Perry & Carroll, 2008; MacKillop et al., 2011), the tendency to discount 
delayed rewards in favor of immediate ones is well-established in substance users and may be 




  The current study examined composite substance use (heroin, cocaine, alcohol, and 
marijuana) as a predictor of adherence in a population of HIV positive low-income substance 
users in a residential treatment facility in Washington DC.  We hypothesize that greater 
substance use severity would be significantly related to poor medication adherence.  
Additionally, this study aimed to examine mediators of this relationship.  We hypothesize 
positive reinforcement from the environment and propensity for immediate rewards would 
mediate the inverse relationship between substance use and medication adherence.   
 The current study aims to address a major limitation in the extant literature- lack of 
investigation into mechanisms that underlie the relationship between substance use and 
medication adherence.  The study also was designed to address other limitation such as a narrow 
focus on individual substances without attention to broader use across substances (e.g., Sharpe et 
al, 2004; Haug et al, 2005; Samet et al, 2006), thereby limiting our understanding of the effect of 
substance use more broadly on medication adherence.  The current study will also address the 
limitation that studies to date have examined individuals in outpatient HIV clinics, in hospitals, 
or in outpatient drug treatment by examining this relationship in a population of inpatient 
substance users, who are at particularly high risk for low or nonadherence.  As an exploratory 
aim, we will examine the incremental explanatory contribution of one substance as compared to 
another for each substance used (heroin, cocaine, alcohol, and marijuana).   
Primary Aims and Hypotheses 
Aim 1: To test substance use severity as a predictor of  daily medication adherence in a sample 
of low-income substance users in residential treatment.  




Aim 2: To test independent mediators of this relationship  
b. A. To test environmental rewards as a mediator of the relationship between 
substance use and low medication adherence. 
1) Hypothesis: Low levels of environmental reward will mediate the 
relationship between higher levels of substance use and lower 
medication adherence.  
c. To test delay discounting as a mediator of the relationship between substance use 
and low medication adherence. 
1) Hypothesis: Greater discounting of future rewards will mediate the 
relationship between higher levels of substance use and lower 
medication adherence. 
Exploratory Aims 
Exploratory Aim 1: To test both mediators (environmental rewards and delay discounting) 
together in a single model.   
Exploratory Aim 2: To test the relationship of each substance (cocaine, opioids, marijuana, and 




Participants in the study were African American (N=84, 43.7% female) inner-city drug 
users (Mage=45.5, SD=8.28) in treatment at a residential drug treatment center, the Salvation 
Army Harbor Light (SAHL) Residential Treatment Center in Northeast Washington, DC. 
Although the percentage of female participants in this study is higher than that of females living 
with HIV/AIDS in the general population (CDC, 2011) this gender breakdown is consistent with 
that of the population of individuals living with HIV at SAHL (Chen et al., 2011). This center 
utilizes a mix of strategies adopted from Alcoholics and Narcotics Anonymous as well as group 
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sessions focused on relapse prevention. SAHL uses regular drug testing and use is grounds for 
dismissal from the center.  HIV positive substance users who are beginning their final month of 
residential treatment was referred by treatment staff at the center for a randomized controlled 
trial investigating Behavioral Activation as a treatment for HIV medication adherence, and the 
current study utilizes baseline data from this trial.  
Measures 
Psychopathology  
The Structured Clinical Interview for the DSM-IV (SCID-IV; First & Gibbon, 2004) was 
used to assess lifetime and current DSM-IV Axis-I psychopathology to determine study 
eligibility. The SCID was conducted by trained interviewers (graduate students and post-
baccalaureate research assistants) during participants’ first week at the substance abuse treatment 
center as part of a screening for eligibility.  
Demographics 
Demographics form assessed age, race/ethnicity, education level, marital status, 
employment status, and annual household income.  
Medication Adherence 
AACTG Adherence to anti-retroviral medications questionnaire (AACTG: Chesney, Morin, 
& Sherr, 2000).  Participants read a set of directions that highlight how difficult it is for many 
patients to adhere to their medication regimens. Patients then provided information for each of 
their medications. For example, a patient would report the following information: (1) name of 
drug, (2) prescribed doses per day, (3) prescribed number of pills per dose, and (4) any special 
directions (i.e. `with food', `on an empty stomach' or `with plenty of fluids'). They were next 
asked about the pills that they took for each of the last two days, including the name of each 
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medication and how many pills they had skipped that day. Patients were also asked two 
additional questions on more distal adherence.  Patients who reported ever skipping their 
medications are given a list of reasons why people may miss taking their medications (e.g. had 
too many pills to take, wanted to avoid side effects, had a change in daily routine) and are asked 
to rate on a four-point scale (never, rarely, sometimes, often) how often each reason applies to 
them.  HIV related health status will also be measures by the AACTG.  Self-reported 
nonadherence was defined as the frequency of reasons endorsed for nonadherence across all 
reasons provided, with higher scores indicating greater nonadherence. This measure was used as 
the main self-report dependent variable of nonadherence.  This is in line with other studies that 
have used a total reasons score as a main adherence outcome (e.g., O’Cleirigh, Ironson, & Smits, 
2007; DiIorio et al., 2009; Magidson et al., 2015) in order to minimize potential inaccuracies of 
self-reported adherence. 
Viral Load: Viral Load, an indicator of HIV disease progression, was also collected at 
baseline.   Medication adherence was corroborated with Viral Load.  Viral load has repeatedly 
demonstrated a significant correlation with HIV medication adherence (Arnsten et al., 2001; 
Glass et al., 2006; Paterson, et al., 2000), with only the most optimal rates of HIV medication 
adherence leading to an undetectable amount of virus in the blood stream (i.e., <50 copies/mL). 
These two adherence measures (self- report and viral load) were included as the dependent 
variables across all Aims; we treated each measure as a separate dependent variable, conducting 
separate analyses for all Aims. 
Substance Use 
Drug Use History Questionnaire (e.g., Babor & Del Boca, 1992; Grant, Contoreggi, & 
London, 2000; Daughters, Lejuez, Bornovalova, et al., 2005). At baseline assessment 
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participants were asked if they have ever used a particular substance in their lifetime, how often 
they used it in the past year prior to treatment, and how often they used the substance during the 
period of their life when they were using it most frequently. The latter two questions are rated on 
a 6-point scale ranging from "never", "one time", "monthly or less", "2 to 4 times a month", "2 to 
3 times a week", and "4 or more times a week." All substances were assessed, but we included 
the most commonly used substances in this sample as the main independent variable because 
they are both the most prevalent substances among the sample at Harbor Light and they are also 
the most commonly studied substances in the literature examining substance use as it relates to 
HAART adherence. These included: (a) cannabis, (b) alcohol, (c) cocaine, and (d) opioids. 
Responses on the DUQ were summed to create an overall score of substance use severity, the 
main independent variable in the analyses (Tull, Bardeen, DiLillo, Messman-Moore, & Gratz, 
2014). 
Environmental Reward  
Reward Probability Index (RPI; Carvalho et al., 2011) is a 20-item scale that is made up 
of two factors- Reward Probability and Environmental Suppressors.  The RPI measures access to 
environmental rewards and response contingent positive reinforcement.  Sample items include: 
“I have many interests that bring me pleasure”, “Changes have happened in my life that have 
made it hard to find enjoyment”, and “I have many opportunities to socialize with people”.  
Participants are asked to rate their responses on a Likert scale ranging from “Strongly Agree” to 
“Strongly Disagree”.  The appropriate items were reverse coded, and the total score was used as 
our mediating variable.  The RPI has high convergent validity (r=.65-.81) with measures of 
activity, avoidance, reinforcement, and depression in a sample of undergraduate students.  It has 
also been used to measure access to environmental rewards in undergraduates with depression 
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(Carvalho et al., 2011), Latinos with elevated depressive symptoms (Collado, Castillo, Maero, 
Lejuez, & MacPherson, 2014). and HIV positive substance users in treatment (Magidson et al., 
2015). Scores on the RPI comprised our mediating variable.       
Delay Discounting 
Monetary Choice Questionnaire (MCQ; Kirby, Petry & Bickel, 1999).  Participants were 
presented a fixed set of 27 choices between smaller, immediate rewards and larger, delayed 
rewards. For example, a participant was asked, “Would you prefer $54 today, or $55 in 11 
days?” The participant indicated which alternative he or she would prefer to receive by circling 
the alternative on the questionnaire.  Responses on the measure were coded into small ($25-$35), 
medium ($50-$60), and large rewards ($75-$85), consistent with grouping of the reward sizes of 
the original measure (Kirby & Maraković, 1996).  These reward magnitudes made up our 
mediating variable.     
Data Analysis 
Primary Aim 1: To test the hypothesis that substance use will have an inverse relationship 
with medication adherence, we employed linear regression analyses.  We examined substance 
use severity as a predictor of medication adherence, controlling for relevant covariates.  Potential 
covariates were identified from the set of theoretically-relevant covariates selected a priori 
(demographic variables, psychopathology, and HIV related health status). Variables that were 
significantly related to HIV medication adherence were included as covariate(s). 
Primary Aims 2.a. and 2.b: To test the hypothesis that substance use will have a negative 
association with medication adherence and that this relation will be mediated by both 
environmental reward (RPI) and delay discounting (MCQ), we examined a mediation model, 
using the Process macro provided by Preacher and Hayes (2008) to calculate total, direct, and 
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indirect effects. The indirect effect of substance use on medication adherence through both RPI 
and MCQ in separate models will be tested using a nonparametric bootstrapping procedure 
(Preacher & Hayes, 2004, 2008). Bootstrapping procedures are considered preferable to other 
approaches because they do not assume normality of the distribution of the indirect effects and 
hence provide stronger protection against Type II error, compared to normal procedures such as 
the Sobel test (Shrout & Bolger, 2002).  We determined the statistical significance of the indirect 
effect by examining the bootstrapped confidence intervals around this effect; confidence 
intervals that do not contain zero are considered significant. Potential covariates were identified 
from the set of theoretically-relevant covariates and were selected a priori (demographic 
variables, psychopathology, and HIV related health status). Variables that were significantly 
related to HIV medication adherence were included as covariate(s). 
Exploratory Aim 1: If significant indirect effects (i.e. the confidence intervals do not 
contain zero) of substance use on medication adherence through either RPI or MCQ are 
established, we will then examine the relative relations between these variables using a parallel 
multiple mediator model following the same approach described above.  
Exploratory Aim 2: We will use a hierarchical multiple regression to examine the 
exploratory aim of testing the relationship of each substance (cocaine, opioids, marijuana, and 
alcohol) with medication adherence. We entered each substance into separate regression models, 
with each one controlling for the other substances (and relevant covariates), to examine the 
incremental effect of each substance on adherence.  Then we entered all substances that were 
significantly related to the outcome into one multiple regression model simultaneously, to 
examine the incremental significance of each drug on the outcome variable, medication 






Data were collected from 84 HIV positive (43.7% female) inner-city drug users 
(Mage=45.5, SD=8.28).  Participants had been diagnosed with HIV an average of 10.24 years 
prior to the study (SD=6.98) and had an average viral load of 15700.80 (SD=45979.28; the virus 
is considered undetectable if the viral load is below 50 copies/mL). 64% of the participants were 
taking HIV medication daily (see Table 1 for descriptions of key study variables for those on 
HAART vs. not on HAART).      
The number of reasons for missing doses ranged from 0-36, and participants reported an 
average of 11.62 reasons for missing their medication (SD=8.8).  Additionally, 15.9% reported 
the last time they missed their medication was in the past week, 11% reported the last time 
missing their medication was 1-2 weeks prior, 6.1% reported that the last time they missed their 
medication was 2-4 weeks ago, 23.2% reported 1-3 months ago, 26.8% more than 3 months ago, 
and 17.1% reported never missing their medication. The sample was characterized by the 
following substance use frequencies at 4 or more times a week in the last year: Alcohol (40%), 
cocaine (37.3%), marijuana (14.1%, opioid (16.4%).  Please see Table 1 for descriptive statistics 
of key study variables and bi-variate correlations, Table 2 for a detailed description of substance 
use frequencies during the past 12 months, and Table 3 for bi-variate correlations among 
substances.   
Hypothesis Tests 
Primary Hypothesis 1: Our first primary hypothesis was that substance use will have an 
inverse relationship to medication adherence.  There were no significant relations among 
demographic or HIV related variables with adherence, and thus we did not include any 
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covariates in this model.  The regression equation was significant, with higher substance use 
scores predicting lower medication adherence (β=.498, SE=.225, F(1,73) =4.91, R²=.063, p=.03).   
Primary Hypothesis 2.a: Our second primary hypothesis was that environmental reward 
would mediate the relation between substance use and poor medication adherence.  For this test, 
we used a bootstrapping method for the construction of a 95% confidence interval (CI) around 
the unstandardized indirect effect (Hayes, 2009; Preacher & Hayes, 2008). The a path was not 
significant (β=.159, F(1,73) =.51, R²=.0069, p=.48).  The b path was significant (β=-.378, 
F(2,72) =8.74, R²=.20, p=.0004).  The c’ path, or the direct effect of environmental reward on the 
relationship between substance use and adherence was significant (β=.5583, SE=.2105, p=.0098, 
CI [.139-.978]), as was the total effect (β=.498, SE=.2248, p=.029, CI [.05-.946], however the 
indirect effect was not significant (.159 × -.378= -.06, CI [-.269-.082]).  The indirect effect was 
not significant.    
Primary Hypothesis 2.b. Our last primary hypothesis was that delay discounting would 
mediate the relation between substance use and poor medication adherence.  We conducted 
separate analyses for small, medium, and large reward magnitude on the MCQ.  The sample size 
for these analyses was N=70 due to missing data.  For these tests, we also used a bootstrapping 
method for the construction of a 95% confidence interval (CI) around the unstandardized indirect 
effect (Hayes, 2009; Preacher & Hayes, 2008).  The indirect effect was not significant for the 
small reward magnitude (-.002 × -4.055= .008, CI [-.05-.16]), medium reward magnitude (0.00 × 
-16.507=0, CI [-.04-.12]), or large reward magnitude (-.002 × 6.993=-.014, CI [-.15-.02]). Thus, 
the hypothesis that delay discounting mediates the relation between substance use and poor 
medication adherence was not supported, regardless of the magnitude of the delayed reward on 
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the MCQ.   See Figure 1 for final model of the relation between substance use and medication 
adherence using these mediators.   
Exploratory Hypothesis 1:  Because the confidence interval contained zero for both of the 
proposed mediators and therefore did not support an indirect effect of either environmental 
reward or delay discounting, we did not test them together in one model.     
Exploratory Hypothesis 2:  As an exploratory aim, we sought to examine the relation 
between each substance (alcohol, marijuana, cocaine, and opioids) and medication adherence.  
We used linear regression to test each drug separately.  We did not control for demographic 
variables (e.g. age, sex) because they were not significantly related to the outcome.  Past year 
alcohol use was significantly related to medication adherence (β=1.5, SE=.51, F(1,65) =8.89, 
R²=.12, p=.004).  Past year marijuana (β=.20, SE=.64, F(1,62) =.09, R²=.002, p=.75), cocaine 
(β=.62, SE=.50, F(1,65) =1.53, R²=.02, p=.221), and heroin use (β=.27, SE=.59, F(1,63) =.21, 
R²=.001, p=.818) were not predictive of low adherence.   
Biological outcomes (Viral Load): 
Primary Aim 1: The regression equation examining past year substance use as a predictor 
of poor adherence was not significant (β=668.45, SE=668.90, F(1,61) =.99, R²=.016, p=.32).   
Primary Hypothesis 2.a: We hypothesized that environmental reward would mediate the 
relation between substance use and poor medication adherence as measured by high viral load.  
The indirect effect was the product .077 × 569.812= -.06, and the bootstrapped CI [-163.18-
826.89].  Because the CI contains zero, the indirect effect was not significant and therefor this 
hypothesis was not supported.   
Primary Hypothesis 2.b: We hypothesized that delay discounting would mediate the 
relation between substance use and poor HIV medication adherence.  We conducted separate 
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analyses for small, medium, and large reward magnitude on the MCQ.  For these tests, we also 
used a bootstrapping method for the construction of a 95% confidence interval (CI) around the 
unstandardized indirect effect (Hayes, 2009; Preacher & Hayes, 2008).  The indirect effect was 
not significant for the small reward magnitude (-.0006 × -69099.63= .008; CI [-221.52-705.24]), 
the medium reward (-.0001 × -105280.39=0; CI [-368.97-631.31]), or the large reward (-.0009 × 
-.114032.5=-.014; CI [-184.63-1019.98]).  Because the CI contained zero for all the reward 
magnitudes, the indirect effects were not significant.  Thus, the hypothesis that delay discounting 
mediates the relation between substance use and poor medication adherence was not supported, 
regardless of the magnitude of the delayed reward on the MCQ.    
Exploratory Hypothesis 1:  Because the indirect effects for the primary aims were not 
significant (i.e. the confidence intervals contained zero), we did not test both proposed mediators 
together in one model using viral load as an outcome.  
Exploratory Hypothesis 2:  As an exploratory aim, we sought to examine the relation 
between each substance (alcohol, marijuana, cocaine, and heroin) and medication adherence 
using viral load as an outcome.  We used linear regression to text each drug separately.  We did 
not control for demographic variables (e.g. age, sex) because they were not significantly related 
to the outcome.  Past year alcohol use (β=-3285.79 SE=3224.08, F(1,59) =1.04, R²=.017, 
p=.312), marijuana use (β=156.46, SE=3676.28 F(1,56) =.002, R²=.00, p=.97), cocaine use 
(β=2503.60, SE=3061.97, F(1,59) =.67, R²=.011, p=.417) and heroin use (β=-4419.21, 
SE=3281.27, F(1,58) =1.81, R²=.03, p=.18) were not related to viral load.  Because none of the 
substances were significantly predictive of viral load, we did not look at the relative contribution 





The purpose of this study was to examine mechanisms explaining the relation between 
substance use and poor medication adherence as measured by frequency of reasons for missing 
doses among HIV positive substance users in residential treatment. This was the first study to our 
knowledge that investigated mechanisms for the relation between substance use and medication 
adherence from a behavioral framework in a sample of HIV positive substance users. We sought 
to establish a temporal relationship between the independent variable (substance use), the 
mediating variables (environmental reward and delay discounting), and the outcome variable 
(medication adherence).  Despite this being a theoretically and data driven hypothesis, our 
findings did not support mediation for either of the proposed mediators. However, we did find 
significant main effects of both substance use and lack of environmental reward on daily 
medication adherence.   
Results of our study supported significant main effects of both substance use and lack of 
positive reinforcement from the environment on adherence, suggesting that both of these 
processes play a role in the maintenance of medication adherence among HIV positive substance 
users. Moreover, both of these constructs accounted for a substantial amount of variance in the 
model, suggesting that they have an additive effect on adherence as measured by frequency of 
reasons for missing medications. The finding that substance use is related to poor adherence is in 
line with our hypotheses and consistent with previous research (Arnsten et al., 2002; Malta et al., 
2008; Stein et al., 2002; Gonzalez et al., 2011). Results of our study also suggest an association 
between lack of environmental contingencies and medication adherence as measured by 
frequency of reasons for missing doses. Our study is one of the first to link lack of environmental 
rewards to medication adherence as measured by frequency of reasons for missing doses. This 
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supports a behavioral theoretical framework that suggest that individuals who value a healthy, 
non-substance using lifestyle are more inclined to take their medication as prescribed. 
The findings from our study did not support mediation with either of our proposed 
variables (lack of environmental reward and delay discounting). One explanation for the absence 
of mediation could be that there are likely reciprocal processes involved in these relationships. 
People who a) lack environmental contingencies and b) discount the value of a delayed reward 
are at risk for initiating and maintaining substance use habits, but also the regular use of 
substances creates an environment that lacks non-substance related reinforcement and also 
promotes discounting of delayed reward due to the immediate reward of using the substance. 
Thus, it is likely that one process increases the likelihood of another, and this pattern continues.  
  It is interesting that our findings did not support an association between substance use 
and lack of access to rewards in the environment. This finding is inconsistent with previous 
research. It is possible that the time of assessment affected this lack of significant findings. 
Participants have been in a restricted environment and thus abstinent from substances for some 
time. They may not exhibit the same lack of enthusiasm for non-substance related activities 
because they now value non-substance related activities as a result of being in drug treatment. 
This is consistent with findings that establish a link between abstinence and an increase in non-
substance related activities (Van Etten et al. 1998).  
Our findings did not support indirect effects of delay discounting on the relation between 
substance use and medication adherence. Results also did not support direct associations between 
delay discounting and substance use or delay discounting and poor adherence. The first result is 
surprising given the substantial body of literature that supports the relation between substance 
use and delay discounting (Madden et al., 1997; Mitchell, 1999; Vuchinich & Simpson, 1998; 
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Kirby & Petry, 2004; Yi et al., 2008), and the lack of association between delay discounting and 
adherence is also surprising given the strong theoretical framework that supports this 
relationship. There are, however factors that could explain this lack of association between delay 
discounting and medication adherence.   
First, the delay discounting measure we used asked about immediate and delayed positive 
rewards, whereas medication adherence is delaying the absence of a negative reward (e.g. a 
delayed negative reinforcement model).  Because the measure did not capture this construct, 
measurement limitations could explain why we did not find the association as predicted. Future 
studies could use a measure that is focused on delaying negative rewards. Additionally, the effect 
of abstinence could be a factor. Substance users who have been abstinent may not discount 
delayed rewards at the same rate they would have if they had been actively using during this 
study. In a similar vein, it could be that the substance use habits of these participants are so 
severe that they no longer use the substances for positive reinforcement reasons, but more so for 
reasons that are consistent with a negative reinforcement model of substance use. If this is the 
case, the value of the monetary reward would be irrelevant regardless of the delay.  
Second, because we did not subdivide the reasons for nonadherence, it might be the case 
that delay discounting does not relate to the total composite, but rather might relate to specific 
domains of behavioral reasons for nonadherence (e.g. avoiding unpleasant side effects, having to 
keep track of a complex regimen). Previous research suggests the reasons for missing medication 
are in fact relevant (Magidson et al., 2015). Future research should parse apart specific reasons 
(e.g. intentional verses unintentional) for low adherence to examine if delay discounting could 
differentially predict specific reasons for nonadherence.    
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Regarding the exploratory aim of testing the individual contribution of each substance, 
we found that alcohol was the only substance that was related to low adherence.  This is 
consistent with prior research that links alcohol use to low medication adherence among HIV 
positive substance users (Hendershot et al., 2009). However, we did not find that any other drug 
independently predicted low adherence, which raises the question of whether alcohol is driving 
the effect, or is it that substance use severity is the important factor, regardless of the specific 
substance.  It is interesting that alcohol and cocaine were used at approximately the same 
frequency in the past year, but alcohol was significantly associated with adherence whereas 
cocaine was not. It could be the case that substance use severity might matter more than alcohol 
use on its own because it accounts for individuals using multiple substances at one time, which is 
common in this sample and is associated with a host of negative outcomes (Tull et al., 2014).  
The findings from the study suggest two potential points for intervention, substance use 
and lack of access to positive rewards in the environment. Because the results did not provide 
specific insight regarding directionality, it would be most beneficial to provide an intervention 
that targets both of these risk factors. Behavioral Activation (Lejuez et al., 2011) is a promising 
treatment that increases access to environmental contingencies. This intervention has been 
proposed for individuals in residential substance use treatment to target substance use (Daughters 
et al., 2008), and to improve medication adherence among HIV positive substance users in 
residential treatment (Daughters et al., 2010).  This treatment is intended to target lack of access 
to a rewarding environment with the goal of decreasing substance use and increasing medication 
adherence and is a promising treatment for this population.  
Limitations and Future Directions 
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There are several limitations to the current study.  First, because the data are cross-
sectional it is difficult to investigate a true mediational model.  Although there is support for 
cross-sectional mediation, future research should use prospective designs to examine the 
longitudinal effects of substance use on medication adherence.  Additionally, although 
nonparametric bootstrapping is well suited for small samples (Preacher & Hayes, 2004, 2008a) 
larger sample size may be needed to detect indirect effects.  Another concern is regarding the 
measurement of adherence. Adherence, or poor adherence, in this case was measured by 
assessing the frequency of reasons for missing medication.  Although this measurement has been 
used in previous research (Magidson et al., 2015; O’Cleirigh et al., 2011), there are significant 
limitations to this proxy for adherence in addition to the self-report nature of the assessment.  It 
is possible, for instance, that an individual may consistently cite one reason for nonadherence 
that happens regularly, while another may have a variety of reasons that happen less frequently. 
Additionally, reasons for missing medications may not translate to actual doses missed. Future 
research should examine substance use, access to environmental reward, and the propensity to 
discount delayed rewards in relation to a more direct measure of adherence. Another limitation 
regarding this outcome variable is that the reasons for missing a medication dose are not parsed 
apart. Risk factors for missing medication due to a behavioral reason (e.g. avoiding unpleasant 
side effects) could be very different from a non-behavioral reason (e.g. thinking it may not help). 
It is possible, for example, that delay discounting could have been related to a certain subset of 
reasons for missing medication, but not the composite reasons score.  Future research should 
parse apart these reasons and investigate the differential risk factors for different types of reasons 
for missing doses.       
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Another limitation of the current study is the measure of substance use.  We used past 
year substance use to predict overall medication adherence.  It is possible that the substance use 
measure was too global, in averaging across more fine-grained patterns of use, to capture a 
lifetime of substance use and its effects on medication adherence. It is also possible that past year 
substance use did not mirror current substance use, and in fact the current pattern of substance 
use was much less frequent than in the past year prior to treatment. Future research should 
examine current substance use and its relation to medication adherence.  
An additional limitation of the current study is that although all of the participants were 
HIV positive, they were not all on HAART. Although there are benefits to examining medication 
adherence in general (e.g. the fact that most individuals with HIV are taking additional non-HIV 
medications), there may be something particularly aversive about HIV medication that promotes 
nonadherence, thus there could be different rates of adherence for different medications, so 
future research should examine the effects of substance use on adherence and potential mediators 
using a sample of individuals all taking HAART. The current sample size was not conducive to 
examining only those on HAART.   
A final limitation of the current study may have been the setting. Data were collected in a 
residential substance use treatment center, which is a restricted environment. This could have an 
effect on medication adherence because it is a controlled environment with access to a nursing 
staff who could help manage adherence. This environment also may also be misrepresentative of 
past year substance use because the participants are often entering the treatment facility from 
another restricted environment, where drug use is prohibited. Together, these factors may limit 
generalizability to the general substance using population with HIV. Nonetheless, this study 
provides insight into the risk factors for poor medication adherence among HIV positive 
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substance users in residential treatment and provides opportunities for further research and 
targeted clinical interventions.  
Future research should address the limitations of the current study including measures of 
substance use and nonadherence, and timing of the assessments. There is also a need for 
prospective studies that examine substance use and medication adherence overtime in order to 
examine possible mediators at various time points and to examine the ways by which medication 
adherence is affected by a lifetime of substance use. Future research might also look at additional 
mediators and moderators of the relation between substance use and low adherence, including 
psychopathology. For instance, there is a strong literature to suggest a relation between 
depression and anxiety and low medication adherence among individuals with HIV/AIDS 
(Safren et al., 2012). There is also a strong relationship between depression and lack of access to 
environmental contingencies, so depression might be a factor that could be incorporated into the 
model in the current study.  
To conclude, the current study sought to extend previous research on the relation between 
substance use and poor medication adherence among HIV positive substance users by examining 
possible mechanism that could explain this relationship, environmental rewards and delay 
discounting. Though neither of our mediation models was supported, this study did shed light on 
the processes that contribute to low adherence, namely substance use and lack of environmental 
contingencies. Consistent with a behavioral framework, access to environmental contingencies is 
imperative when considering the complexity of reasons for missing daily medication. Future 
research is needed to address the limitations of and to extend the current study in order to gain a 
complete picture of the processes that contribute to low adherence among vulnerable 
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